Application of anti-human EMC10 monoclonal antibody in prevention and treatment of type 2 diabetes mellitus

• Main Authors: CHEN KUANGYANG, WANG XUANCHUN, JING YU, HU RENMING, LI YANLIANG
• Format: Patent
• Language: Chinese; English
• Published: 08.03.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention discloses an application of an anti-human EMC10 monoclonal antibody in prevention and treatment of type 2 diabetes mellitus. The invention discloses application of an anti-human EMC10 monoclonal antibody in preparation of a product for treating and/or preventing diabetes mellitus. The monoclonal antibody can specifically recognize an epitope with an amino acid sequence shown as SEQ ID No.5. The invention further discloses a preparation method of the anti-human EMC10 monoclonal antibody. The anti-EMC10 monoclonal antibody provided by the invention obviously reduces the blood glucose of a type 2 diabetes mouse model, improves the glucose tolerance and insulin sensitivity of the mouse, can be used for preparing products for treating or preventing diabetes, and provides a brand new treatment target for diabetes. 本发明公开了抗人EMC10的单克隆抗体在防治2型糖尿病中的应用。本发明公开了抗人EMC10的单克隆抗体在制备治疗和/或预防糖尿病的产品中的应用，所述单克隆抗体能特异性识别氨基酸序列如SEQ ID No.5所示的抗原表位。本发明提供的抗EMC10的单克隆抗体显著降低2型糖尿病小鼠模型的血糖，提高小鼠的糖耐量和胰岛素敏感性，可用于制备治疗或预防糖尿病的产品，为糖尿病提供了一个全新的